# ![@IroquoiInvest Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1375645595487076353.png) @IroquoiInvest Iroquois Investments

Iroquois Investments posts on X about $srpt, has been, longterm, $envx the most. They currently have [---] followers and [--] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1375645595487076353/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1375645595487076353/c:line/m:interactions.svg)

- [--] Week [---] +688%
- [--] Month [-----] +13%
- [--] Months [------] +12,288%
- [--] Year [------] +22,891%

### Mentions: [--] [#](/creator/twitter::1375645595487076353/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1375645595487076353/c:line/m:posts_active.svg)

- [--] Month [--] -83%
- [--] Months [--] +1,050%
- [--] Year [--] +900%

### Followers: [---] [#](/creator/twitter::1375645595487076353/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1375645595487076353/c:line/m:followers.svg)

- [--] Week [---] +1.60%
- [--] Month [---] +0.81%
- [--] Months [---] +25%
- [--] Year [---] +39%

### CreatorRank: [---------] [#](/creator/twitter::1375645595487076353/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1375645595487076353/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  81.36% [finance](/list/finance)  10.17% [cryptocurrencies](/list/cryptocurrencies)  8.47% [technology brands](/list/technology-brands)  3.39% [exchanges](/list/exchanges)  1.69%

**Social topic influence**
[$srpt](/topic/$srpt) #18, [has been](/topic/has-been) 5.08%, [longterm](/topic/longterm) 5.08%, [$envx](/topic/$envx) 3.39%, [$frog](/topic/$frog) 3.39%, [adoption](/topic/adoption) 3.39%, [$vtsi](/topic/$vtsi) 3.39%, [$rgnx](/topic/$rgnx) 3.39%, [$sldb](/topic/$sldb) 3.39%, [cmo](/topic/cmo) 1.69%

**Top accounts mentioned or mentioned by**
[@commonsenseplay](/creator/undefined) [@alohaoasis](/creator/undefined) [@yachmod](/creator/undefined) [@sarepta](/creator/undefined) [@marksharkking](/creator/undefined) [@richtrades100](/creator/undefined) [@abacusgm](/creator/undefined) [@johnhempton](/creator/undefined) [@fidelisaurelius](/creator/undefined) [@towiu2](/creator/undefined) [@tequilavernetti](/creator/undefined) [@adamfeuersteins](/creator/undefined)

**Top assets mentioned**
[Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Enovix Corporation Common Stock (ENVX)](/topic/$envx) [Frodo the virtual samurai (FROG)](/topic/$frog) [Broadcom, Inc. (AVGO)](/topic/$avgo) [NVIDIA Corp. (NVDA)](/topic/$nvda) [OctoFi (OCTO)](/topic/$octo) [SILK (SILK)](/topic/$silk) [Barclays PLC (BCS)](/topic/barclays-plc) [Airbloc (ABL)](/topic/$abl) [Avidity Biosciences, Inc. (RNA)](/topic/$rna) [CRISPR Therapeutics AG (CRSP)](/topic/$crsp) [Intellia Therapeutics, Inc (NTLA)](/topic/$ntla) [Bluefin (BLUE)](/topic/$blue) [BEAM (BEAM)](/topic/$beam) [Vertex Protocol (VRTX)](/topic/$vrtx) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Many still see Sarepta as a one-drug company because of Elevidys. But in reality $SRPT is building the foundation to run multiple RNA drugs in parallel. They're investing in supply chain manufacturing and planning for scale $SRPT dropped an update recently that went unnoticed in my opinion: a new Director Supply Chain & CMO Outsourcing (Procurement) posting focused on . siRNA program development and clinical material supply and commercial launch readiness. That lines up perfectly with https://t.co/QDR2ZRvZqR $SRPT dropped an update recently that went unnoticed in my opinion: a new Director"  
[X Link](https://x.com/IroquoiInvest/status/2020133118154342735)  2026-02-07T13:50Z [---] followers, [----] engagements


"This is beyond f**ked. If scientists at the FDA are being handed scripts to sign then what the hell are we even calling science anymore And were supposed to trust this clown process to fairly $SRPT Richard Pazdur a longtime regulator said politics risks outweighing science at the agency. https://t.co/6YCHF6yHKX Richard Pazdur a longtime regulator said politics risks outweighing science at the agency. https://t.co/6YCHF6yHKX"  
[X Link](https://x.com/IroquoiInvest/status/2022624749839409396)  2026-02-14T10:51Z [---] followers, [---] engagements


"Broadcom Inc. (AVGO) Stock Sinks As Market Gains: What You Should Know #stockmarketnews https://finance.yahoo.com/news/broadcom-inc-avgo-stock-sinks-214509248.html https://finance.yahoo.com/news/broadcom-inc-avgo-stock-sinks-214509248.html"  
[X Link](https://x.com/IroquoiInvest/status/1661160080858054656)  2023-05-24T00:00Z [---] followers, [--] engagements


"Been considering the potential impact of the #3Dprinting industry on #Sustainability and think there are many instances where these technologies can reduce production waste & pollution. A good example are printers coming from edgy companies like $NNDM"  
[X Link](https://x.com/anyuser/status/1721185447789883765)  2023-11-05T15:19Z [--] followers, [--] engagements


"#Crypto Payments Firm BCB Group Was the Subject of an FCA Investigation"  
[X Link](https://x.com/IroquoiInvest/status/1842183943728038220)  2024-10-04T12:44Z [--] followers, [--] engagements


"Nvidia #Stock Could Soar Another 38% According to [--] Wall Street Firm Thoughts $NVDA https://www.fool.com/investing/2024/10/25/nvidia-stock-could-soar-another-38-according-to-1/ https://www.fool.com/investing/2024/10/25/nvidia-stock-could-soar-another-38-according-to-1/"  
[X Link](https://x.com/IroquoiInvest/status/1850785887094759610)  2024-10-28T06:25Z [---] followers, [--] engagements


"@AlohaOasis No one is saying Elevidys is perfect. But its giving real kids a second chance at life. These kids arent waiting for perfection theyre just hoping for a chance and that should be enough"  
[X Link](https://x.com/IroquoiInvest/status/1942294041913164088)  2025-07-07T18:46Z [--] followers, [--] engagements


"$SRPT The science on ambulatory kids has been consistent: Lower dose younger immune system no AAV exposure. SRPT did what was asked. But instead of building on that progress were watching politics and fear drown out science"  
[X Link](https://x.com/IroquoiInvest/status/1949894311333564776)  2025-07-28T18:06Z [---] followers, [----] engagements


"$ENVX Lets just say the final $$$ wont fit in a single slide @IroquoiInvest Wonder what the final $$$ will be @IroquoiInvest Wonder what the final $$$ will be"  
[X Link](https://x.com/IroquoiInvest/status/1962508737559609538)  2025-09-01T13:31Z [---] followers, [---] engagements


"15% bear case = full withdrawal. 45% base case = ambulatory approval. 40% bull case = broad label in 12-24 months. Do the math odds are stacked for $SRPT I've been spending a lot of time analysing $SRPT and have come up with a risk-weighted valuation chart. Bear (PMO only): $9/share 15% probability Central (Ambulatory only): $38/share 45% probability Bull (Broad resumption): $102/share 40% probability The red dashed line https://t.co/mxQvEvgZGz I've been spending a lot of time analysing $SRPT and have come up with a risk-weighted valuation chart. Bear (PMO only): $9/share 15% probability"  
[X Link](https://x.com/IroquoiInvest/status/1962553160381214972)  2025-09-01T16:28Z [---] followers, [---] engagements


"$SRPT Yeah because dying before kindergarten is so much safer. $SRPT Slow down be safe Tell that to families where 30% of kids die before [--]. Delays kill. Elevidys saves. https://t.co/Bc67ZTJOz1 $SRPT Slow down be safe Tell that to families where 30% of kids die before [--]. Delays kill. Elevidys saves. https://t.co/Bc67ZTJOz1"  
[X Link](https://x.com/IroquoiInvest/status/1964033283823427852)  2025-09-05T18:29Z [---] followers, [---] engagements


"$SRPT Manufacturing IP patient registries. Sarepta owns that moat in DMD"  
[X Link](https://x.com/IroquoiInvest/status/1965115028421706220)  2025-09-08T18:08Z [---] followers, [----] engagements


"$SRPT Gene therapy valuations across biotech point to far higher multiples once execution stabilizes. Keep focusing on Srpts unique moat in neuromuscular disease. $SRPT Manufacturing IP patient registries. Sarepta owns that moat in DMD. https://t.co/bp4hZdnOc5 $SRPT Manufacturing IP patient registries. Sarepta owns that moat in DMD. https://t.co/bp4hZdnOc5"  
[X Link](https://x.com/IroquoiInvest/status/1965115643738644742)  2025-09-08T18:10Z [---] followers, [----] engagements


"Dont care how many scary headlines they throw at $SRPT this is still the only game in town for Duchenne. Ive been reading families posts about their sons literally walking running riding bikes again after Elevidys. You cant unsee that"  
[X Link](https://x.com/IroquoiInvest/status/1965498793182572544)  2025-09-09T19:33Z [---] followers, [----] engagements


"FDA drama will come and go but $srpt has the IP the manufacturing and the patient trust. Stock has been nuked but thats exactly why Im watching it here. Risk/reward is wild but man it feels asymmetric. Dont care how many scary headlines they throw at $SRPT this is still the only game in town for Duchenne. Ive been reading families posts about their sons literally walking running riding bikes again after Elevidys. You cant unsee that. Dont care how many scary headlines they throw at $SRPT this is still the only game in town for Duchenne. Ive been reading families posts about their sons"  
[X Link](https://x.com/IroquoiInvest/status/1965499228685525457)  2025-09-09T19:35Z [---] followers, [----] engagements


"@yachmod @Sarepta Competition wouldnt even be in the conversation if FDA hadnt spent the last year tripping $SRPT with delays and mixed signals"  
[X Link](https://x.com/IroquoiInvest/status/1966030234030854144)  2025-09-11T06:45Z [---] followers, [---] engagements


"If Citadel is on the hook here Im grabbing popcorn. $OCTO SETS A NASDAQ WORLD RECORD [--] DAY GAIN OF 30x FROM $1.72 TO $72 IN ONE DAY CITADEL IS LIKELY GETTING SQUEEZED INCREASING THEIR POSITION AS A DELTA HEDGE AGAINST THEIR LOSSES SELLING THE STOCK SHORT Bitminer invested $20 million in OCTO now worth $550 million Shorts Get https://t.co/L1OeONFDmH $OCTO SETS A NASDAQ WORLD RECORD [--] DAY GAIN OF 30x FROM $1.72 TO $72 IN ONE DAY CITADEL IS LIKELY GETTING SQUEEZED INCREASING THEIR POSITION AS A DELTA HEDGE AGAINST THEIR LOSSES SELLING THE STOCK SHORT Bitminer invested $20 million in OCTO now"  
[X Link](https://x.com/IroquoiInvest/status/1966030555457454132)  2025-09-11T06:46Z [---] followers, [--] engagements


"$FROG about to leap out the pond. Shorts better pray it doesnt grow wings"  
[X Link](https://x.com/IroquoiInvest/status/1966569024700973203)  2025-09-12T18:26Z [---] followers, [--] engagements


"Families know Elevidys doctors know Elevidys insurers are paying for Elevidys. $SRPT s moat is deeper than bears want to admit"  
[X Link](https://x.com/IroquoiInvest/status/1966577208480190530)  2025-09-12T18:58Z [---] followers, [----] engagements


"People be sleepin on $SRPT Elevidys doesnt need better marketing it needs earlier diagnoses. If newborn screening passes Srpts addressable market triples"  
[X Link](https://x.com/IroquoiInvest/status/1967680265503100930)  2025-09-15T20:01Z [---] followers, [----] engagements


"@commonsenseplay $SRPT s patient base gonna explode if newborn screening passes"  
[X Link](https://x.com/IroquoiInvest/status/1967683080866402572)  2025-09-15T20:12Z [---] followers, [---] engagements


"$SRPT The potential for Elevidys is massive if diagnosis gets earlier. Folks forget that most boys are diagnosed way too late for gene therapy to fully work"  
[X Link](https://x.com/IroquoiInvest/status/1967687216626647511)  2025-09-15T20:29Z [---] followers, [----] engagements


"$FROG has been one of the cleanest setups on Sei. Steady grind higher"  
[X Link](https://x.com/IroquoiInvest/status/1968017474168951046)  2025-09-16T18:21Z [---] followers, [--] engagements


"FDAs clock is unpredictable but the point is $SRPT has got multiple shots on goal lined up. Label change ENVOL newborn screening plus revenue surprising to the upside feels like shorts betting on silence are ignoring the build up"  
[X Link](https://x.com/IroquoiInvest/status/1968018654727115105)  2025-09-16T18:26Z [---] followers, [----] engagements


"$SRPT [--] year hold. BlueCross recently reversed denials after families appealed which shows coverage will keep expanding IMO. ENVOL could move Elevidys into younger kids"  
[X Link](https://x.com/IroquoiInvest/status/1969091141430575345)  2025-09-19T17:28Z [---] followers, [----] engagements


"$SRPT If 43% of doctors already show $95m in [--] weeks the other half is the iceberg under the waterline. What the market calls uncertainty is actually underreported adoption"  
[X Link](https://x.com/IroquoiInvest/status/1969134401033310277)  2025-09-19T20:20Z [---] followers, [----] engagements


"$SRPT Last update Sept [--] [----]. [--] pts across [--] age cohorts (4yo) Long-term 208w follow-up Endpoints refined: dystrophin expression motor function Roche + Sarepta still funding They are actively building the next label expansion https://clinicaltrials.gov/study/NCT06128564cond=DMD&term=Envol&rank=1&a=11&tab=history#outcome-measures-card https://clinicaltrials.gov/study/NCT06128564cond=DMD&term=Envol&rank=1&a=11&tab=history#outcome-measures-card"  
[X Link](https://x.com/IroquoiInvest/status/1970170224109371445)  2025-09-22T16:56Z [---] followers, [----] engagements


"@MarkSharkKing No formal survey Dec [----]. If anything adoption was stronger then. Whats impressive is that even after all the noise 40% docs still on board. Demand held up"  
[X Link](https://x.com/IroquoiInvest/status/1970218359401656638)  2025-09-22T20:07Z [---] followers, [--] engagements


"@richtrades100 Yep. Trust with Wall st is a process but trust with patients is already there. Hard for the market to ignore $SRPT forever"  
[X Link](https://x.com/IroquoiInvest/status/1970220860943573346)  2025-09-22T20:17Z [---] followers, [---] engagements


"In a few years Elevidys will be everywhere DMD is. Elevidys is the future of Duchenne treatment. $SRPT will own that lane"  
[X Link](https://x.com/IroquoiInvest/status/1974181909014905283)  2025-10-03T18:37Z [---] followers, [----] engagements


"$SRPT This 3-year readout backs up every bullish case weve made: - Durable efficacy - Expanding market (non-ambulatory label) - Long-term revenue runway The question is how far it can go Shorts better start running the 10MWR too"  
[X Link](https://x.com/IroquoiInvest/status/1975987921300881436)  2025-10-08T18:13Z [---] followers, [----] engagements


"$SRPT Thats a funny way of admitting theyre still holding up three years later. Whats new is the full 3-year durability confirmation the matched external control analysis and the fact that every endpoint is now statistically validated across cohorts. Adam why are you not reporting on the $SRPT Elevidys 3-yr data being presented today at WMS Because these very same data were already presented at conferences in May and March. The data ARE NOT NEW. Adam why are you not reporting on the $SRPT Elevidys 3-yr data being presented today at WMS Because these very same data were already presented at"  
[X Link](https://x.com/IroquoiInvest/status/1976018104795922841)  2025-10-08T20:13Z [---] followers, [----] engagements


"$SRPT The story isnt that its old The story is that its still "true" af man If this were negative youd have written five articles by now Adam But its positive so suddenly its nothing new" $SRPT Thats a funny way of admitting theyre still holding up three years later. Whats new is the full 3-year durability confirmation the matched external control analysis and the fact that every endpoint is now statistically validated across cohorts. $SRPT Thats a funny way of admitting theyre still holding up three years later. Whats new is the full 3-year durability confirmation the matched external"  
[X Link](https://x.com/IroquoiInvest/status/1976019337455849577)  2025-10-08T20:18Z [---] followers, [----] engagements


"$SILK CFO Lucas Buchanan sold [-----] shares of the business's stock in a transaction that occurred last week. The shares were sold at an average price of $61.43 for a total value of $614300"  
[X Link](https://x.com/IroquoiInvest/status/1389259461525712903)  2021-05-03T16:44Z [---] followers, [--] engagements


"DeFi tokens witness a significant decline down over 80% against ETH since their all-time highs. #DeFi #PriceDecline https://finance.yahoo.com/news/defi-tokens-down-over-80-194753442.html https://finance.yahoo.com/news/defi-tokens-down-over-80-194753442.html"  
[X Link](https://x.com/IroquoiInvest/status/1668380404951445504)  2023-06-12T22:11Z [---] followers, [--] engagements


"VirTra Inc. (NASDAQ:VTSI) Shares Acquired by Barclays PLC $VTSI https://www.defenseworld.net/2025/01/24/virtra-inc-nasdaqvtsi-shares-acquired-by-barclays-plc.html https://www.defenseworld.net/2025/01/24/virtra-inc-nasdaqvtsi-shares-acquired-by-barclays-plc.html"  
[X Link](https://x.com/IroquoiInvest/status/1884124051221942683)  2025-01-28T06:19Z [---] followers, [--] engagements


"Is VirTra (NASDAQ:VTSI) Using Too Much Debt $VTSI #stockmarket https://simplywall.st/stocks/us/capital-goods/nasdaq-vtsi/virtra/news/is-virtra-nasdaqvtsi-using-too-much-debt https://simplywall.st/stocks/us/capital-goods/nasdaq-vtsi/virtra/news/is-virtra-nasdaqvtsi-using-too-much-debt"  
[X Link](https://x.com/IroquoiInvest/status/1890489738819207266)  2025-02-14T19:54Z [--] followers, [--] engagements


"$SRPT Functional stabilization across NSAA RFF 10MWR - durability isnt a promise anymore its data. Folks said gene therapy couldn't hold up past [--] months. The kids just proved them wrong for [--] straight. So yeah in the future there will be robots and Elevidys. @IroquoiInvest In the future there will be robots and Elevidys 🤖🧬 @IroquoiInvest In the future there will be robots and Elevidys 🤖🧬"  
[X Link](https://x.com/IroquoiInvest/status/1976709143349096502)  2025-10-10T17:59Z [---] followers, [----] engagements


"Abacus ($ABL) just closed a $50M securitization of life-insurance assets. Above-investment-grade sold to institutional buyers. Quiet but notable step for longevity-linked credit- the asset class is starting to look more mainstream. #ABL #AlternativeAssets #LongevityFinance "Abacus $ABL Sells $50 Million of Securitized Life Insurance Assets to Institutional Investors" @AbacusGM "Transaction Structured as an Above Investment Grade-Rated Collateralized Note Abacus Global Management Inc. a leader in alternative asset management announced that it "Abacus $ABL Sells $50 Million of Securitized Life"  
[X Link](https://x.com/IroquoiInvest/status/1981395437115625592)  2025-10-23T16:20Z [---] followers, [--] engagements


"$SRPT Eleven boys all improving. Small cohort but every kid got better. Safetys manageable nothing unexpected. You start early you preserve function its that simple. $SRPT Another single-center study (CHOP). "All patients showed improvements in motor outcomes." https://t.co/FyZSvhRevy $SRPT Another single-center study (CHOP). "All patients showed improvements in motor outcomes." https://t.co/FyZSvhRevy"  
[X Link](https://x.com/IroquoiInvest/status/1981756935113212229)  2025-10-24T16:17Z [---] followers, [----] engagements


"$SRPT If they even hit half that list we'll be cooking. What I'd love to see from $srpt ER: - Guidance (just do amb guidance w/e) - Rev Beat and no losses (probs will have a loss but one can dream) - Buyback - non-amb update (new stuff no rehashes pls) - Pipeline updates (positive sounding) Am i asking for a lot Hehe What I'd love to see from $srpt ER: - Guidance (just do amb guidance w/e) - Rev Beat and no losses (probs will have a loss but one can dream) - Buyback - non-amb update (new stuff no rehashes pls) - Pipeline updates (positive sounding) Am i asking for a lot Hehe"  
[X Link](https://x.com/IroquoiInvest/status/1983215953644044289)  2025-10-28T16:55Z [---] followers, [----] engagements


"$SRPT SRP9003 still has a shot. The expression data are solid the safety signals cleaner than expected and sirolimus could be their ticket back in FDAs good graces. Its a high-risk lane but if they pull it off that pivot to siRNA turns into a two-front comeback IMHO"  
[X Link](https://x.com/IroquoiInvest/status/1983243618556227595)  2025-10-28T18:45Z [---] followers, [----] engagements


"$SRPT still looks cheap af. RNA gets 12B for promises while SRPT gets 6B for products. Funny how the market loves a prototype but sleeps on a pioneer. 1/2) So $RNA gets 12b$ for clinical stage DMD treatment for Exon44 (7% DMD patients) while $SRPT is in commercial stage for DMD Exon [--] [--] & [--] (30% DMD patients) with already 1.3b$ sales booked in H1 [----] and a massive clinical pipeline more advanced and sofisticated vs $RNA https://t.co/yd9LDu1r38 1/2) So $RNA gets 12b$ for clinical stage DMD treatment for Exon44 (7% DMD patients) while $SRPT is in commercial stage for DMD Exon [--] [--] & 53"  
[X Link](https://x.com/IroquoiInvest/status/1983938208241958983)  2025-10-30T16:45Z [---] followers, [---] engagements


"$SRPT datas been sitting there for months and these people are busy un-firing each other. Dude talks about rigor 24/7 but cant keep a single senior researcher in the building. Wheres the science he keeps preaching about Exclusive: Vinay Prasad has rattled FDA staff by expanding his power and pushing out senior leaders. https://t.co/Che0Pv4c7i Exclusive: Vinay Prasad has rattled FDA staff by expanding his power and pushing out senior leaders. https://t.co/Che0Pv4c7i"  
[X Link](https://x.com/IroquoiInvest/status/1984344125387440593)  2025-10-31T19:38Z [---] followers, [----] engagements


"$SRPT Several Keytruda and Opdivo trials missed their prespecified primary endpoints (KEYNOTE-061 CheckMate-026 etc.) before becoming standard of care. The same logic applies here a statistical miss doesnt erase clinical relevance. @John_Hempton Did you not read anything . $SRPT's PMO's do work. Not meeting the primary endpoint does not mean they don't benefit the patients. Which of these cancer drugs do not work they all failed their primary endpoints and are still available on the market helping cancer patients: @John_Hempton Did you not read anything . $SRPT's PMO's do work. Not meeting"  
[X Link](https://x.com/IroquoiInvest/status/1986550601296011309)  2025-11-06T21:45Z [---] followers, [----] engagements


"@commonsenseplay @FidelisAurelius $srpt lmao I still dont get it. How is adding [--] years of life 3-4 years of walking and 3-7 years of breathing not considered "work" Asking seriously"  
[X Link](https://x.com/IroquoiInvest/status/1986554035877363917)  2025-11-06T21:59Z [---] followers, [---] engagements


"$SRPT The confirmatory trial missed its primary endpoint yes. But it also showed a consistent functional trend in non COVID participants and aligns with long term real-world data. Calling that no efficacy oversimplifies a complex dataset. The confirmatory trial confirmed it has no efficacy. The confirmatory trial confirmed it has no efficacy"  
[X Link](https://x.com/IroquoiInvest/status/1987583465190039665)  2025-11-09T18:10Z [---] followers, [----] engagements


"$SRPT Every DMD gene therapy after Elevidys is still in early or mid-phase. Theyll need: -5-6 years of clean long-term safety and functional efficacy data -2-3 years more to scale AAV production and global logistics"  
[X Link](https://x.com/IroquoiInvest/status/1989036384988893492)  2025-11-13T18:23Z [---] followers, [----] engagements


"$srpt By the time theyre ready Elevidys will have a decade of real-world proof and global sales. It takes years of biology manufacturing and follow-up data and SRPT has already done all three. Call it whatever you want but its still a one-horse race $SRPT Every DMD gene therapy after Elevidys is still in early or mid-phase. Theyll need: -5-6 years of clean long-term safety and functional efficacy data -2-3 years more to scale AAV production and global logistics $SRPT Every DMD gene therapy after Elevidys is still in early or mid-phase. Theyll need: -5-6 years of clean long-term safety and"  
[X Link](https://x.com/IroquoiInvest/status/1989037268057682159)  2025-11-13T18:26Z [---] followers, [----] engagements


"$SRPT Yep no more guessing games. With the label set its just pure execution and clinical data from here. This is the version of Elevydis weve been waiting to see. $SRPT FDA approves new labeling for Elevidys. Reaffirming our initial thesis that Elevidys would end up remaining on the market for ambulatory DMD patients. Very rough 'napkin' valuation -- shows Sarepta offers upside with Elevidys clarity provided. https://t.co/MjdpV3KgJB $SRPT FDA approves new labeling for Elevidys. Reaffirming our initial thesis that Elevidys would end up remaining on the market for ambulatory DMD patients. Very"  
[X Link](https://x.com/IroquoiInvest/status/1989736404281184396)  2025-11-15T16:45Z [---] followers, [----] engagements


"@TOWiU2 Anyone who actually followed the timeline knows $SRPT voluntarily narrowed the label months before the FDA made anything official. But with all the chaos inside the agency lately its not shocking that the public story gets twisted while the real sequence gets lost"  
[X Link](https://x.com/IroquoiInvest/status/1990648410525876634)  2025-11-18T05:09Z [---] followers, [---] engagements


"$SRPT Amen $SRPT Access to treatment has been publicly promised Any reversal deserves a clear and transparent explanation to American people. For families and patients who depend on these therapies it is hope time and life. The FDA should not allow decisions that take that away lightly $SRPT Access to treatment has been publicly promised Any reversal deserves a clear and transparent explanation to American people. For families and patients who depend on these therapies it is hope time and life. The FDA should not allow decisions that take that away lightly"  
[X Link](https://x.com/IroquoiInvest/status/2001734909409345669)  2025-12-18T19:22Z [---] followers, [---] engagements


"$SRPT worth emphasizing that this isnt just about detection. HHS wouldnt make this move if early intervention didnt meaningfully change the disease trajectory. Thats the signal here. @TequilaVernetti Additionally $srpt $rgnx $sldb - Key quote : As HHS noted approved gene therapies have been shown to dramatically improve outcomes in managing the disease. Early diagnosis and treatment are critical to help children keep their abilities longer from : https://t.co/c1vr710ZRW @TequilaVernetti Additionally $srpt $rgnx $sldb - Key quote : As HHS noted approved gene therapies have been shown to"  
[X Link](https://x.com/IroquoiInvest/status/2001736706769211845)  2025-12-18T19:29Z [---] followers, [----] engagements


"Thank you This is satisfying to read. Early screening only makes sense when early treatment works and its good to see Elevidys and $SRPT starting to be discussed on that basis @IroquoiInvest $srpt Thats what HHS official said in Newsweek etc: https://t.co/XHN7NpenoC https://t.co/NcuoNpeZym @IroquoiInvest $srpt Thats what HHS official said in Newsweek etc: https://t.co/XHN7NpenoC https://t.co/NcuoNpeZym"  
[X Link](https://x.com/IroquoiInvest/status/2003543378726912149)  2025-12-23T19:09Z [---] followers, [---] engagements


"$SRPT Elevidys is holding up pipelines moving. Thats why Mizuho stayed constructive. Now its just about seeing the next data. $SRPT : Mizuho reiterates maintains  $ Analyst upbeat on Elevidys sales trajectory and pipeline enthusiasm following mgmts update on sirolimus studies and early-stage data. https://t.co/dmLPKnSQGB $SRPT : Mizuho reiterates maintains  $ Analyst upbeat on Elevidys sales trajectory and pipeline enthusiasm following mgmts update on sirolimus studies and early-stage data. https://t.co/dmLPKnSQGB"  
[X Link](https://x.com/IroquoiInvest/status/2011850176454152235)  2026-01-15T17:17Z [---] followers, [---] engagements


"If $Srpt disappeared tomorrow rebuilding what they own would cost way more than current EV"  
[X Link](https://x.com/IroquoiInvest/status/2013294546130452763)  2026-01-19T16:56Z [---] followers, [----] engagements


"$SRPT Criticism should inform readers not prosecute a single narrative regardless of how the evidence evolves. Adams takes dont seem to. He keeps pushing the same negative take year after year no matter what the data shows. Over the past [--] months @adamfeuersteins X posts about Sarepta ( $SRPT ) show an unusually consistent and aggressive negative narrative - often echoing amplifying or previewing themes later used in STAT coverage. $SRPT $SLDB $RGNX $CRSP $EDIT $NTLA $BEAM $VRTX $REGN $BLUE https://t.co/N4noKK11no Over the past [--] months @adamfeuersteins X posts about Sarepta ( $SRPT ) show"  
[X Link](https://x.com/IroquoiInvest/status/2015407205885899068)  2026-01-25T12:51Z [---] followers, [---] engagements


"$SRPT The consistent divergence over three years across multiple functional measures is difficult to explain by improvements in SoC alone. Slower decline perhaps. But reversal and compounding divergence over three years point far more convincingly to a treatment effect. $SRPT improving SoC over the past 10y did the heavy lifting here not Elevidys. Next year NSAA from baseline will go into the red and the decline curve will resume. https://t.co/dImjfeNqJY $SRPT improving SoC over the past 10y did the heavy lifting here not Elevidys. Next year NSAA from baseline will go into the red and the"  
[X Link](https://x.com/IroquoiInvest/status/2015858022648521038)  2026-01-26T18:43Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing